Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Exp Dermatol. 2008 Mar 13;17(9):752–760. doi: 10.1111/j.1600-0625.2008.00716.x

Figure 2.

Figure 2

Tetracycline (TCN) dose-dependently inhibits adenosine-5′-triphosphate (ATP)γS-induced CXCL1 production. (a) Human microvascular endothelial cell line-1 (HMEC-1) cells were cultured in the presence of TCN for 30 min followed by addition of ATPγS to 100 μM. Supernatants were collected 24 h later and analysed for CXCL1 content. Note that ATPγS enhances CXCL1 release. Error bars indicate ± SD (P = 0.004, 0.0002 and 0.0001, respectively, for TCN of 1, 3 and 10 μg/ml compared with 0 μg/ml for the ATPγS-treated groups). TCN also significantly inhibited non-stimulated production (P < 0.002 and P = 0.0125, respectively, for TCN of 3 and 10 μg/ml compared with 0 μg/ml for the ATPγS groups). (b) Primary human dermal microvascular endothelial cells were cultured in the presence of TCN for 30 min followed by addition of ATPγS to 100 μM. The supernatants were collected 24 h later and analysed for CXCL1 content. Note that ATPγS enhances CXCL1 release. Error bars indicate ± SD (P = 0.003, 0.002, 0.001, <0.001 and <0.001, respectively, for TCN 3, 10, 20, 40 and 80 μg/ml compared with 0 μg/ml for the ATPγS-treated groups).